RENOVUE-65
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOVUE-65 is an injectable NDA approved in 1978 by Bracco with unknown mechanism of action and indication profile. The product's mechanism of action and therapeutic class remain undisclosed in available data.
LOE Approaching
Product is in terminal lifecycle phase with minimal commercial expansion; team size likely stabilized or contracting as LOE nears.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring activity for RENOVUE-65 roles. Working on this product offers stability in a mature/declining asset but limited upward mobility or skill-building in growth areas.
Brand ManagerRegional Sales Manager
Worked on RENOVUE-65 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.